They have also shown that bispecific CAR T cells targeting both CD19 and CD22 can recognize and kill CD19+CD22+, CD19−CD22+, and CD19+CD22− B-ALL, pointing towards a strategy able to overcome anti-CD19 CAR T cell limitations [37]. Here, CD22 is linked to acute lymphoblastic leukemia.